JAGUAR HEALTH, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
JAGUAR HEALTH, INC. (JAGX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of -0.20% for the 12-month period ending 2018-12-31, per its 10-K filed 2020-04-03.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2020-04-03
- JAGUAR HEALTH, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2018 was -0.20%.
- JAGUAR HEALTH, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2017 was -0.20%, a 140.00% decline from fiscal 2016.
- JAGUAR HEALTH, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2016 was 0.50%.
- JAGUAR HEALTH, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2015 was -5.20%, a 750.00% decline from fiscal 2014.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|
| 2018-12-31 | -0.20% 10-K · filed 2020-04-03 | |
| 2017-12-31 | -0.20% 10-K · filed 2019-04-10 | 0.20% 10-K · filed 2018-04-09 |
| 2016-12-31 | 0.50% 10-K · filed 2018-04-09 | |
| 2015-12-31 | -5.20% 10-K · filed 2017-02-15 | |
| 2014-12-31 | 0.80% 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |